Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Viatris

Tracked across 4 events · 59 articles · First seen Apr 04, 2025 · Last active Sep 08, 2026

Sentiment
5
Attention
6
Events
4
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 20
Regulatory
Impact: Viatris received FDA approval for Gwyn Lo, a new once-weekly contraceptive patch with low-dose estrogen, expanding its women's health portfolio. The approval is a positive regulatory milestone, though commercial impact depends on launch timing, pricing, and payer coverage.
Jul 29, 2026 · 6 articles
4 0
Business
Impact: Viatris is currently facing a pending lawsuit from the estate of Henrietta Lacks regarding the use of HeLa cells.
Feb 26, 2026 · 7 articles
4 0
Business
Moody s Ratings and S&P Global Ratings assigned investment-grade credit ratings to Sun Pharma Industries, India's largest pharmaceutical company, in connection with its proposed USD 11.75 billion acquisition of US-based Organon & Co. S&P assigned…
Impact: Viatris is mentioned as a comparable peer with annual revenues of USD 14-17 billion, illustrating the competitive landscape Sun Pharma will enter.
Sep 08, 2026 · 6 articles
6 0
Business
Impact: Biocon acquired Viatris' global biosimilars business for over $3 billion, consolidating its position in the market.
May 05, 2026 · 40 articles
ERGEN INTELLIGENCE
Track Viatris live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.